Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Patient was triple vaccinated with Moderna and got COVID / tested positive for COVID on 28May2022; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Patient was triple vaccinated with Moderna and got COVID / tested positive for COVID on 28May2022) in a 37-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Sleep apnea (Patient had sleep apnea and uses CPAP.).   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-May-2022, the patient experienced COVID-19 (Patient was triple vaccinated with Moderna and got COVID / tested positive for COVID on 28May2022). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) on 28-May-2022 for COVID-19 treatment, at a dose of 1 dosage form twice a day. At the time of the report, COVID-19 (Patient was triple vaccinated with Moderna and got COVID / tested positive for COVID on 28May2022) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-May-2022, SARS-CoV-2 test: positive (Positive) Positive.         The patient reported he was short, fat and ethnicity as white.  Concomitant medications were not reported.  It was reported patient had never got the Pfizer vaccine. Patient was triple vaccinated with Moderna and got COVID. Patient was administered a sample of the emergency use of Paxlovid. The only major side effect patient had horrible taste in mouth. Patient had almost no COVID symptoms except fatigue. The patient had sleep apnea and uses CPAP. Since being on Paxlovid. the events recorded by CPAP have dropped to zero. Patient apnea events had dropped to zero using the Paxlovid medication. It was almost a treatment for sleep apnea. The patient had tested positive for COVIID-19 on 28-May-2022 with a home test.  Company comment This spontaneous case reported by a patient, concerns a 37-year-old male patient with concurrent illness with Sleep apnoea, who experienced the unexpected, non serious AESI of covid 19, unknown days after receiving the 3 dose of mRNA-1273 vaccine in the covid 19 vaccination series. Patient received the 2 primary doses of Moderna vaccines at unknown dates. On 28-May-2022, SARS-CoV-2 test was positive and the patient experienced COVID-19. It was reported that the patient was treated with Nirmatrelvir, Ritonavir (Paxlovid), at a dose of 1 dosage form twice a day from 28 May, for covid 19 treatment. Event outcome was unknown. The patient reported that he was short and obese with a BMI of 38.65. Patient had almost no COVID symptoms except fatigue. The patient had sleep apnea and used Continuous Positive Airway Pressure(CPAP). The apnea events had completely stopped after using the Paxlovid medication. Obesity and ongoing Covid 19 pandemia are confounders.The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per Medical judgement.   Most recent FOLLOW-UP information incorporated above includes: On 02-Jun-2022: Non-significant followup received QE (Quality complaint no.) added.; Sender's Comments: This spontaneous case reported by a patient, concerns a 37-year-old male patient with concurrent illness with Sleep apnoea, who experienced the unexpected, non serious AESI of covid 19, unknown days after receiving the 3 dose of mRNA-1273 vaccine in the covid 19 vaccination series. Patient received the 2 primary doses of Moderna vaccines at unknown dates. On 28-May-2022, SARS-CoV-2 test was positive and the patient experienced COVID-19. It was reported that the patient was treated with Nirmatrelvir, Ritonavir (Paxlovid), at a dose of 1 dosage form twice a day from 28 May, for covid 19 treatment. Event outcome was unknown. The patient reported that he was short and obese with a BMI of 38.65. Patient had almost no COVID symptoms except fatigue. The patient had sleep apnea and used Continuous Positive Airway Pressure(CPAP). The apnea events had completely stopped after using the Paxlovid medication. Obesity and ongoing Covid 19 pandemia are confounders.The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per Medical judgement.